Pharmacologic interactions between transdermal selegiline and cocaine

J. Mendelson, A. S. Dearborn, N. Uemura, Laeben Lester, N. Chiang, P. Jacob, R. T. Jones

Research output: Contribution to journalArticle

Abstract

Selegiline may be efficacious in treatment of cocaine addiction. This study assessed pharmacokinetic (PK) and pharmacodynamic (PD) interactions between transdermal (TD) selegiline and cocaine in 14 nondependent, cocaine-experienced volunteers challenged with IV cocaine-d5 before and after TD selegiline. To obtain steady state conditions for cocaine rapidly, a 0.5 mg/kg loading dose (over 10 min) was followed by a 4 hr infusion of 2.0 mg/kg. Transdermal selegiline was administered as one 20 mg/patch/day (Somerset Pharmaceuticals) applied after the first cocaine infusion and continued for 10 days. The second cocaine challenge was performed following 1 days of selegiline, at selegiline steady-state (determined by urine PK analysis). PD effects of cocaine (heart rate, blood pressure, respiratory rate, skin and tympanic temperature) were not altered by selegiline. Adverse reactions to TD selegiline were minimal with no orthostatic vital sign changes and no adverse cardiovascular reactions. Selegiline and its levo-metabolites had all reached steady-state after approximately 5 days. Plasma cocaine PK was unaffected by selegiline administration. These results suggest that TD selegiline is safe and may be useful in the treatment of cocaine dependence.

Original languageEnglish (US)
JournalClinical Pharmacology and Therapeutics
Volume69
Issue number2
StatePublished - 2001
Externally publishedYes

Fingerprint

Selegiline
Cocaine
Cocaine-Related Disorders
Pharmacokinetics
Skin Temperature
Vital Signs
Respiratory Rate
Volunteers
Heart Rate

ASJC Scopus subject areas

  • Pharmacology

Cite this

Mendelson, J., Dearborn, A. S., Uemura, N., Lester, L., Chiang, N., Jacob, P., & Jones, R. T. (2001). Pharmacologic interactions between transdermal selegiline and cocaine. Clinical Pharmacology and Therapeutics, 69(2).

Pharmacologic interactions between transdermal selegiline and cocaine. / Mendelson, J.; Dearborn, A. S.; Uemura, N.; Lester, Laeben; Chiang, N.; Jacob, P.; Jones, R. T.

In: Clinical Pharmacology and Therapeutics, Vol. 69, No. 2, 2001.

Research output: Contribution to journalArticle

Mendelson, J, Dearborn, AS, Uemura, N, Lester, L, Chiang, N, Jacob, P & Jones, RT 2001, 'Pharmacologic interactions between transdermal selegiline and cocaine', Clinical Pharmacology and Therapeutics, vol. 69, no. 2.
Mendelson, J. ; Dearborn, A. S. ; Uemura, N. ; Lester, Laeben ; Chiang, N. ; Jacob, P. ; Jones, R. T. / Pharmacologic interactions between transdermal selegiline and cocaine. In: Clinical Pharmacology and Therapeutics. 2001 ; Vol. 69, No. 2.
@article{62f52160159649d38252f88779114e11,
title = "Pharmacologic interactions between transdermal selegiline and cocaine",
abstract = "Selegiline may be efficacious in treatment of cocaine addiction. This study assessed pharmacokinetic (PK) and pharmacodynamic (PD) interactions between transdermal (TD) selegiline and cocaine in 14 nondependent, cocaine-experienced volunteers challenged with IV cocaine-d5 before and after TD selegiline. To obtain steady state conditions for cocaine rapidly, a 0.5 mg/kg loading dose (over 10 min) was followed by a 4 hr infusion of 2.0 mg/kg. Transdermal selegiline was administered as one 20 mg/patch/day (Somerset Pharmaceuticals) applied after the first cocaine infusion and continued for 10 days. The second cocaine challenge was performed following 1 days of selegiline, at selegiline steady-state (determined by urine PK analysis). PD effects of cocaine (heart rate, blood pressure, respiratory rate, skin and tympanic temperature) were not altered by selegiline. Adverse reactions to TD selegiline were minimal with no orthostatic vital sign changes and no adverse cardiovascular reactions. Selegiline and its levo-metabolites had all reached steady-state after approximately 5 days. Plasma cocaine PK was unaffected by selegiline administration. These results suggest that TD selegiline is safe and may be useful in the treatment of cocaine dependence.",
author = "J. Mendelson and Dearborn, {A. S.} and N. Uemura and Laeben Lester and N. Chiang and P. Jacob and Jones, {R. T.}",
year = "2001",
language = "English (US)",
volume = "69",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Pharmacologic interactions between transdermal selegiline and cocaine

AU - Mendelson, J.

AU - Dearborn, A. S.

AU - Uemura, N.

AU - Lester, Laeben

AU - Chiang, N.

AU - Jacob, P.

AU - Jones, R. T.

PY - 2001

Y1 - 2001

N2 - Selegiline may be efficacious in treatment of cocaine addiction. This study assessed pharmacokinetic (PK) and pharmacodynamic (PD) interactions between transdermal (TD) selegiline and cocaine in 14 nondependent, cocaine-experienced volunteers challenged with IV cocaine-d5 before and after TD selegiline. To obtain steady state conditions for cocaine rapidly, a 0.5 mg/kg loading dose (over 10 min) was followed by a 4 hr infusion of 2.0 mg/kg. Transdermal selegiline was administered as one 20 mg/patch/day (Somerset Pharmaceuticals) applied after the first cocaine infusion and continued for 10 days. The second cocaine challenge was performed following 1 days of selegiline, at selegiline steady-state (determined by urine PK analysis). PD effects of cocaine (heart rate, blood pressure, respiratory rate, skin and tympanic temperature) were not altered by selegiline. Adverse reactions to TD selegiline were minimal with no orthostatic vital sign changes and no adverse cardiovascular reactions. Selegiline and its levo-metabolites had all reached steady-state after approximately 5 days. Plasma cocaine PK was unaffected by selegiline administration. These results suggest that TD selegiline is safe and may be useful in the treatment of cocaine dependence.

AB - Selegiline may be efficacious in treatment of cocaine addiction. This study assessed pharmacokinetic (PK) and pharmacodynamic (PD) interactions between transdermal (TD) selegiline and cocaine in 14 nondependent, cocaine-experienced volunteers challenged with IV cocaine-d5 before and after TD selegiline. To obtain steady state conditions for cocaine rapidly, a 0.5 mg/kg loading dose (over 10 min) was followed by a 4 hr infusion of 2.0 mg/kg. Transdermal selegiline was administered as one 20 mg/patch/day (Somerset Pharmaceuticals) applied after the first cocaine infusion and continued for 10 days. The second cocaine challenge was performed following 1 days of selegiline, at selegiline steady-state (determined by urine PK analysis). PD effects of cocaine (heart rate, blood pressure, respiratory rate, skin and tympanic temperature) were not altered by selegiline. Adverse reactions to TD selegiline were minimal with no orthostatic vital sign changes and no adverse cardiovascular reactions. Selegiline and its levo-metabolites had all reached steady-state after approximately 5 days. Plasma cocaine PK was unaffected by selegiline administration. These results suggest that TD selegiline is safe and may be useful in the treatment of cocaine dependence.

UR - http://www.scopus.com/inward/record.url?scp=2342623544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342623544&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:2342623544

VL - 69

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -